Pancreas News and Research

RSS

The pancreas is a gland organ in the digestive and endocrine system of vertebrates. It is both an endocrine gland producing several important hormones, including insulin, glucagon, and somatostatin, as well as an exocrine gland, secreting pancreatic juice containing digestive enzymes that pass to the small intestine. These enzymes help in the further breakdown of the carbohydrates, protein, and fat in the chyme.

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).

10 Feb 2011

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.

9 Feb 2011

Dream Foundation to fulfill final dream for Stage III Pancreatic Cancer patient

On February 6, Dream Foundation, the first national wish-granting organization for adults in the end stages of life, will fulfill Ed Demyan's final dream - to witness the ultimate American sporting event, the Super Bowl. Demyan, 47, of Brooklyn, Ohio, is a proud father three daughters (11, 14, 22) and a future step-daughter (15).

5 Feb 2011

Immunomedics reports net loss of $3.4M in total revenues for second quarter 2011

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial results for the second quarter ended December 31, 2010.

5 Feb 2011

Viewpoints: Judge Vinson's decision and Sarah Palin, Voting Rights Act; States' Medicaid 'burden;' Global fund controversy

With news coverage focused on Federal District Judge Roger Vinson's decision Monday to declare the health care reform law unconstitutional, it might be easy to miss this week's news from another federal courthouse: opponents of the Voting Rights Act have renewed their efforts to have that law declared unconstitutional, too.

5 Feb 2011

Researchers identify regulatory defect that drives lupus

Researchers at Dana-Farber Cancer Institute in Cambridge, Mass., in collaboration with Jackson Laboratory scientists, have identified a regulatory defect that drives lupus.

4 Feb 2011

JDRF, Eli Lilly sign agreement to fund type 1 diabetes research for re-generative medicine

Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.

4 Feb 2011

Cedars-Sinai receives California Institute grant to develop new technique for specific diseases

A team of scientists from the Cedars-Sinai Regenerative Medicine Institute has been awarded a $1.9 million grant from the California Institute for Regenerative Medicine to fund development of a new technique to aid pharmaceutical discoveries for specific diseases.

3 Feb 2011

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Eli Lilly and Company and Bristol-Myers Squibb Company announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC).

3 Feb 2011

New study to address causes and risk factors of ovarian cancer in African American women

University Hospitals Case Medical Center and Case Western Reserve University School of Medicine are conducting an important new study addressing the lack of knowledge about causes and risk factors for ovarian cancer in African American women. The five-year study is funded by the National Cancer Institute through Case Western Reserve University School of Medicine.

2 Feb 2011

New robotic technique can better predict tumors during radiotherapy, prevent severity of side effects

Medical physicists at Thomas Jefferson University and Jefferson's Kimmel Cancer Center have demonstrated a new real-time tumor tracking technique that can help minimize the amount of radiation delivered to surrounding healthy tissue in a patient—up to 50 percent less in some cases—and maximize the dose the tumor receives.

2 Feb 2011

American Cancer Society reports racial disparity continues to increase death rate for some cancers

While the overall death rate for cancer continues to drop among African Americans, the group continues to have higher death rates and shorter survival of any racial and ethnic group in the U.S. for most cancers. The findings come from Cancer Facts & Figures for African Americans 2011-2012, the latest edition of a report produced every two years by the American Cancer Society.

1 Feb 2011

Budget woes lead states to seek ways to ease Medicaid's requirements

While The Hill reports that CMS administrator Donald Berwick says his agency is trying to help states find solutions, National Journal notes that mounting budgetary pressure has put the program in "dire fiscal straits."

29 Jan 2011

PCMD forms 6M research and analysis network to investigate role of virus infection in type 1 diabetes

The Peninsula College of Medicine and Dentistry (PCMD), University of Exeter, is one of 13 academic institutions and businesses across Europe to form a -6m research and analysis network, funded by the EU for a five-year period, which is designed to investigate the possible role of virus infection in the cause of type 1 diabetes.

28 Jan 2011

Researchers discover new sensory neurons that mediate BP and metabolism regulation in liver

For 60 years, scientists have puzzled over the possibility of a hepatic osmoreceptor that influences blood pressure regulation. Now, researchers of the Max Delbr-ck Center for Molecular Medicine Berlin-Buch, the Experimental and Clinical Research Center of the MDC and Charit- and the Hannover Medical School appear to have made a breakthrough discovery.

27 Jan 2011

Elimination of glucagon action may help convert Type 1 diabetes into non-insulin-dependent disorder

Type 1 diabetes could be converted to an asymptomatic, non-insulin-dependent disorder by eliminating the actions of a specific hormone, new findings by UT Southwestern Medical Center researchers suggest.

27 Jan 2011

Raptor completes enrollment in DR Cysteamine Phase 3 clinical trial in cystinosis

Raptor Pharmaceutical Corp., today announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

24 Jan 2011

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

23 Jan 2011

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that repeated therapy cycles of its proprietary antibody, clivatuzumab tetraxetan, labeled with yttrium-90 plus low-dose gemcitabine, extended median overall survival.

21 Jan 2011

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

NewLink Genetics Corporation today announced that additional data from its Phase 2 clinical trial of the company's investigational HyperAcute® Pancreas cancer immunotherapy will be presented during a poster session at the American Society of Clinical Oncology 2011 Gastrointestinal Cancers Symposium in San Francisco, California.

21 Jan 2011

Pancreas News and Research

Further Reading

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

Repligen third quarter total revenue increases 26% to $7,068,000

Dream Foundation to fulfill final dream for Stage III Pancreatic Cancer patient

Immunomedics reports net loss of $3.4M in total revenues for second quarter 2011

Viewpoints: Judge Vinson's decision and Sarah Palin, Voting Rights Act; States' Medicaid 'burden;' Global fund controversy

Researchers identify regulatory defect that drives lupus

JDRF, Eli Lilly sign agreement to fund type 1 diabetes research for re-generative medicine

Cedars-Sinai receives California Institute grant to develop new technique for specific diseases

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

New study to address causes and risk factors of ovarian cancer in African American women

New robotic technique can better predict tumors during radiotherapy, prevent severity of side effects

American Cancer Society reports racial disparity continues to increase death rate for some cancers

Budget woes lead states to seek ways to ease Medicaid's requirements

PCMD forms 6M research and analysis network to investigate role of virus infection in type 1 diabetes

Researchers discover new sensory neurons that mediate BP and metabolism regulation in liver

Elimination of glucagon action may help convert Type 1 diabetes into non-insulin-dependent disorder

Raptor completes enrollment in DR Cysteamine Phase 3 clinical trial in cystinosis

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News